approved as a therapy for cataplexy or excessive daytime sleepiness in children aged 7 years or older and adults who have narcolepsy, a chronic and debilitating neurologic condition for which there is no cure." />
Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 22 July 2020 | By Renee Matthews
Tags: FDA, US
Regulatory Focus newsletters
All the biggest regulatory news and happenings.